Aurora's CBD Lozenge Partnership: Here's Where To Find The New Product
Aurora's CBD Lozenge Partnership: Here's Where To Find The New Product
Canadian medical cannabis company Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, announced on Monday the launch of the newly developed Luo CBD lozenge.
加拿大醫用大麻公司奧羅拉大麻公司（納斯達克股票代碼：ACB）（多倫多證券交易所股票代碼：ACB）和健康和醫療保健領域的創新者Vectura Fertin Pharma, Inc. 週一宣佈推出新開發的Luo CBD潤喉糖。
What Happened
發生了什麼
The product was developed by Vectura Fertin Pharma, and represents the company's first medical cannabis CBD lozenge to be introduced in Canada.
該產品由Vectura Fertin Pharma開發，是該公司在加拿大推出的第一款醫用大麻CBD潤喉糖。
The move follows the announced commercial collaboration between Vectura Fertin Pharma's subsidiary Cogent International and the Edmonton, Alberta-based company to leverage Aurora's Canadian medical cannabis patient platform.
此舉是在Vectura Fertin Pharma的子公司Cogent International與這家總部位於艾伯塔省埃德蒙頓的公司宣佈進行商業合作以利用Aurora的加拿大醫用大麻患者平台之後採取的。
Cogent manufactures, packages and labels the CBG lozenge, a novel dissolvable format and is easy to dose.
Cogent 製造、包裝和貼標 CBG 潤喉糖，這是一種新型的可溶解形式，易於給藥。
Read Also: Aurora Cannabis Shares Jump On Q1 FY25 Earnings, Global Medical Marijuana Yields Record Revenue Of $343M
另請閱讀：Aurora Cannabis股價在25財年第一季度的收益上漲，全球醫用大麻的收入創紀錄的3.43億美元
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 每天在收件箱中免費獲取Benzinga的獨家分析以及有關大麻行業和市場的熱門新聞。在這裏訂閱我們的時事通訊。如果你認真對待這項業務，就不能錯過這個機會。
Why It Matters
爲什麼重要
Through Aurora's patient platform, Cogent will gain access to patient feedback on the CBD lozenge, which will be used to validate the product proposition and build real-world patient data to inform future products.
通過Aurora的患者平台，Cogent將獲得患者對CBD lozenge的反饋，該反饋將用於驗證產品主張並建立真實的患者數據，爲未來的產品提供信息。
"As the leading provider of medical cannabis in Canada, the launch of the newly developed Luo CBD lozenge on our platform is a significant and exciting milestone at the beginning of our strategic collaboration with Vectura Fertin Pharma," said Aurora CEO Miguel Martin. "We are committed to bringing innovative solutions to patients and this launch reinforces our position at the forefront of Canada's medical cannabis industry."
奧羅拉首席執行官米格爾·馬丁表示：「作爲加拿大領先的醫用大麻供應商，我們在平台上推出新開發的Luo CBD潤喉糖，這是我們與Vectura Fertin Pharma戰略合作之初的一個重要而激動人心的里程碑。」「我們致力於爲患者提供創新的解決方案，此次發佈鞏固了我們在加拿大醫用大麻行業前沿的地位。」
What's Next
下一步是什麼
The two companies are open to exploring opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.
兩家公司願意探索加拿大其他Vectura Fertin Pharma醫用大麻產品的潛在商業化機會。
ACB Price Action
ACB 價格走勢
Aurora's shares traded 2.96% higher at $5.57 per share during the pre-market session on Monday morning.
在週一上午的盤前交易中，Aurora的股價上漲了2.96％，至每股5.57美元。
- NASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership
- 納斯達克大麻巨頭奧羅拉可以通過這種新的CBD Lozenge合作伙伴關係將銷售額增長31％
譯文內容由第三人軟體翻譯。